A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Conditions

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.

Find out more about who can participate in this trial

Trial with
Mirati Therapeutics
Start Date
05/27/2022
End Date
12/01/2022

For more information about this study, contact:

Priscilla Stéve

203.737.2445
priscilla.steve@yale.edu

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Navid Hafez, MD, MPH
Assistant Professor; Assistant Professor (Medical Oncology)

Sub-Investigators

Joseph Kim, MD
Joseph Paul Eder, MD
Luciano V. Del Priore, MD, PhD
Mandy DeMerchant
Michael Cecchini, MD
Ninani Kombo, MD
Patricia LoRusso, DO

Last Updated
07/12/2022
Study HIC
#2000026742

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information